This medication is used for the treatment of various bacterial infections, such as urinary tract, respiratory, gastrointestinal infections, and others caused by susceptible microorganisms. The combination of sulfamethoxazole and trimethoprim works by inhibiting folate synthesis in bacteria, which prevents their growth and reproduction.
The consumption of this product is the responsibility of whoever recommends it and whoever uses it. Consult your doctor before consuming any medication.
THERAPEUTIC INDICATIONS:
Acute otitis media: Co-trimoxazole is used in children and adults for the treatment of acute otitis media (AOM) caused by susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when the clinician makes the trial that the drug offers some use of surplus the advantage of a single anti-infective. Limited data to date regarding safety of repeated use of co-trimoxazole in pediatric patients under 2 years of age, the drug should not be administered prophylactically or for long periods for treatment of otitis media in any age group .
Several antibiotics, including oral amoxicillin, amoxicillin and clavulanate potassium oral different oral cephalosporins (cefaclor, cefdinir, cefixime, cefpodoxil proxetil, cefprozil, ceftibuten, acetyl cefuroxime, cephalexin), IM ceftriaxone, oral co-trimoxazole, erythromycin-sulfisoxazole oral , oral azithromycin, clarithromycin, oral, and oral loracarbef, have been used in the treatment of the AAP, CDC, and other clinicians suggest that, despite the increasing prevalence of S. Multidrug-resistant pneumoniae and Haemophilus influenzae the presence of ß-lactamase producer or M. catarrhalis in many communities, amoxicillin remains the first choice anti-infective for treatment of AOM straightforward because amoxicillin is highly effective, has a narrow spectrum of activity, is well distributed in the middle ear fluid, and is well tolerated. Co-trimoxazole is not considered a first line agent for the treatment of AOM, but is recommended as an alternative for individuals with some type of hypersensitivity to penicillin, because S. pneumoniae resistant to amoxicillin are also often resistant to co-trimoxazole, clarithromycin, and azithromycin
CONTRAINDICATIONS: BACTIVER * is contraindicated in severe hepatic parenchymal disease, blood dyscrasias and severe renal insufficiency, when there is no identifiable plasma regularly.
BACTIVER * not be administered to patients with a history of hypersensitivity to sulfonamides or trimethoprim.Do not administer during pregnancy and lactation, even in preterm infants and infants under 3 months old.
BACTIVER * not be administered to patients with serious blood disorders. Has been given co-trimoxazole in patients undergoing cytotoxic therapy with little or no additional effect on bone marrow or peripheral blood.
BACTIVER * not be given to premature or term infants during the neonatal period.
CAUTIONS: BACTIVER * should be used with caution in patients with impaired renal or liver function, or those with folate deficiency (elderly chronic alcoholics, patients receiving anticonvulsant therapy, patients with intestinal malabsorption and poor nutritional status) and all with allergy and asthma problems.
In patients with glucose-6-phosphate dehydrogenase hemolysis may occur. In elderly patients, may increase the possibility of adverse reactions, particularly when there are complications such as renal function impairment or hepatic impairment.
BACTIVER * not be used for periods longer than 15 days without strict medical supervision.
DOSAGE AND ADMINISTRATION:
Standard Dose: The standard dose for adults and children over 12 years are listed below:
Standard dose for adults and children over 12 years:
Forte tablets
morning
night
standard dose
1
1
Minimum dose and dose therapy
long term (more than 14 days)
½
½
High dose (particularly for cases
serious mind)
1 ½
1 ½
The best way to take BACTIVER ® F is after meals, with an adequate amount of fluids.
Duration of treatment: acute, BACTIVER ® F should be administered for at least 5 days or until the patient shows no symptoms for 2 days minimum. If no clinical improvement is evident after 7 days of therapy, the patient should be reassessed.
